A widely prescribed, FDA-approved epilepsy medication, levetiracetam, may offer a groundbreaking approach to preventing Alzheimer’s disease long before symptoms appear, according to new research from Northwestern University. The findings, published in Science Translational Medicine, suggest the drug can block the production of a toxic protein linked to the disease, potentially reframing strategies for brain-aging interventions.

Alzheimer’s disease is marked by the accumulation of amyloid-beta 42, a sticky protein fragment that forms plaques, kills neurons, and drives memory loss. Traditional therapies focus on clearing plaques once they are present. However, the Northwestern team’s research suggests that levetiracetam acts earlier in the process, preventing the production of the harmful protein rather than attempting to reverse existing damage.

“Our study reveals a mechanism that prevents the formation of amyloid-beta 42 peptides and plaques, rather than just removing them after they’ve formed,” said Dr. Jeffrey Savas, associate professor of behavioral neurology at Northwestern University Feinberg School of Medicine and corresponding author of the study. “This opens doors for new therapeutic strategies and drug targets aimed at early intervention.”

The research demonstrates that amyloid-beta 42 accumulates in synaptic vesicles, tiny sacs used by neurons to communicate. Levetiracetam slows part of the vesicle recycling process by binding to the SV2A protein, keeping amyloid precursor protein (APP) on the neuron surface and steering it away from harmful processing pathways. This subtle rerouting may prevent the toxic buildup that triggers Alzheimer’s pathology.

Timing is critical. Middle-aged brains naturally resist harmful protein pathways, but as the protective mechanisms weaken with age, amyloid-beta 42 production increases, leading to tau tangles, cell death, and eventually dementia. Early intervention, potentially decades before traditional diagnostic tests can detect elevated amyloid levels, may be key to preventing the disease.

Analysis of existing patient data further supports the drug’s potential. Using records from the National Alzheimer’s Coordinating Center, researchers found that patients who had taken levetiracetam experienced a modest but meaningful delay in cognitive decline compared with those on other anti-seizure medications or none at all.

Additionally, examination of brain tissue from individuals with Down syndrome, a population at high risk for early-onset Alzheimer’s, showed early presynaptic protein changes that precede synapse loss and dementia. These findings suggest that levetiracetam or improved derivatives could intervene long before clinical symptoms emerge.

While levetiracetam is not a permanent solution and is rapidly cleared from the body, the study highlights the potential of early pharmacological intervention to protect the aging brain and slow Alzheimer’s progression.